OpenLB
Open Library of Bioscience
Advanced Search
Irish journal of medical science
Oct, 2022;191 (5): 2193-2200.

Does information by pharmacists convince the public to get vaccinated for pneumococcal disease and herpes zoster?

Aygin Bayraktar-Ekincioglu, Emre Kara, Melda Bahap, Mustafa Cankurtaran, Kutay Demirkan, Serhat Unal
Author Information
  1. Aygin Bayraktar-Ekincioglu: Faculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Ankara, Turkey. aygin@hacettepe.edu.tr.
  2. Emre Kara: Faculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Ankara, Turkey.
  3. Melda Bahap: Faculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Ankara, Turkey.
  4. Mustafa Cankurtaran: Faculty of Medicine, Department of Internal Medicine, Division of Geriatrics, Hacettepe University, Ankara, Turkey.
  5. Kutay Demirkan: Faculty of Pharmacy, Department of Clinical Pharmacy, Hacettepe University, Ankara, Turkey.
  6. Serhat Unal: Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Hacettepe University, Ankara, Turkey.
PMID: 34708289 DOI: 10.1007/s11845-021-02778-x

Abstract

BACKGROUND: Pneumococcal diseases (PN) and herpes zoster (HZ) are preventable infections in the adult population.
AIMS: This study aimed to identify the vaccination rates at 1 year after pharmacist-led provision of information in the community. The objectives were to reveal the reasons for not being vaccinated and to determine opinions and awareness of PN and HZ vaccination among public.
METHODS: A prospective study was conducted in five social and solidarity centres in Turkey. Participants were educated by a pharmacist about PN and HZ diseases, vaccinations and reimbursement status, respectively. All Participants were followed by telephone 1 year after to determine their vaccination status.
RESULTS: A total of 155 Participants (72.9% male; mean age was 68.72 ± 9.04 years) were included. With respect to PN and HZ vaccines, it was found that 40% and 12.7% of Participants knew about the respective vaccines. Following the pharmacist's educational session, 52.9% and 51.6% were willing to have the respective vaccine, but only 5.7% and 0.8% respectively got vaccinated 1 year after the educational session. Perceived disease severity, provision of information by a pharmacist, and reimbursement status of the vaccines were not associated with the vaccination rates.
CONCLUSIONS: The public obtain information on vaccines from friends and family members, which may result in misinformation and inappropriate behaviour in vaccination. Although educational sessions provided by pharmacists did not increase the actual vaccination rates for PN and HZ, public willingness to vaccination has increased.

Keywords

Herpes zoster Pharmacist Pneumococcal diseases Vaccination Willingness

References

  1. Tazkarji B, Lam R, Lee S, Meiyappan S (2016) Approach to preventive care in the elderly. Can Fam Physician 62(9):717–721 [PMID: 27629666]
  2. Blasi F, Mantero M, Santus P, Tarsia P (2012) Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 18(Suppl 5):7–14. https://doi.org/10.1111/j.1469-0691.2012.03937.x [DOI: 10.1111/j.1469-0691.2012.03937.x]
  3. Schmedt N, Schiffner-Rohe J, Sprenger R et al (2019) Pneumococcal vaccination rates in immunocompromised patients-a cohort study based on claims data from more than 200,000 patients in Germany. PLoS ONE 14(8):e0220848. https://doi.org/10.1371/journal.pone.0220848 [DOI: 10.1371/journal.pone.0220848]
  4. Vila-Córcoles A, Ochoa-Gondar O, de Diego C et al (2019) Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Euro Surveill 24 (29).  https://doi.org/10.2807/1560-7917.Es.2019.24.29.1800446
  5. The Centers for Disease Control and Prevention (CDC) (2017) Vaccination coverage among adults in the United States, National Health Interview Survey, 2017. Available at: www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html . Access date: April 15, 2021.
  6. Worz C, Martin CM, Travis C et al (2017) Vaccines for Older Adults. Consult Pharm 32(Suppl C):6–13. https://doi.org/10.4140/TCP.s.2017.006 [DOI: 10.4140/TCP.s.2017.006]
  7. Oxman MN, Levin MJ, Johnson GR, et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New Engl J Med 352(22):2271–2284. https://doi.org/10.1056/NEJMoa051016 [DOI: 10.1056/NEJMoa051016]
  8. Lydick E, Epstein RS, Himmelberger D, White CJ (1995) Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 45(12):S52–S53. https://doi.org/10.1212/WNL.45.12_Suppl_8.S52 [DOI: 10.1212/WNL.45.12_Suppl_8.S52]
  9. Matanock A, Lee G, Gierke R et al (2019) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 68(46):1069–1075. https://doi.org/10.15585/mmwr.mm6846a5 [DOI: 10.15585/mmwr.mm6846a5]
  10. Terlizzi EP, Black LI (2018) Shingles vaccination among adults aged 60 and over: United States, 2018. NCHS Data Brief, no 370. Hyattsville, MD: National Center for Health Statistics. 2020.
  11. Healthy People (2020) immunization and infectious diseases objectives. Office of Disease Prevention and Health Promotion. Available at https://www.healthypeople/gov/2020/topics-objectives/topic/immunization-and-infectiousdiseases/objectives . Accessed date: April 15, 2021.
  12. The World Health Organisation Immunization coverage. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage . Accessed 30.09.2019
  13. Centers for Disease Control and Prevention (2016) Vaccination coverage among adults in the United States, National Health Interview Survey 2016. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2016.html . Accessed 30.09.2019
  14. Kan T, Zhang J (2018) Factors influencing seasonal influenza vaccination behaviour among elderly people: a systematic review. Public Health 156:67–78. https://doi.org/10.1016/j.puhe.2017.12.007 [DOI: 10.1016/j.puhe.2017.12.007]
  15. Blasi F, Akova M, Bonanni P et al (2017) Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. Eur J Intern Med 37:13–18. https://doi.org/10.1016/j.ejim.2016.09.024 [DOI: 10.1016/j.ejim.2016.09.024]
  16. Satman I, Akalin S, Cakir B et al (2013) The effect of physicians’ awareness on influenza and pneumococcal vaccination rates and correlates of vaccination in patients with diabetes in Turkey an epidemiological study “diaVAX.” Hum Vacc Immunother 9(12):2618–2626. https://doi.org/10.4161/hv.25826 [DOI: 10.4161/hv.25826]
  17. Lam ACY, Chan MY, Chou HY et al (2017) A cross-sectional study of the knowledge, attitude, and practice of patients aged 50 years or above towards herpes zoster in an out-patient setting. Hong Kong Med J 23(4):365–373. https://doi.org/10.12809/hkmj165043 [DOI: 10.12809/hkmj165043]
  18. Paek E, Johnson R (2010) Public Awareness and knowledge of herpes zoster: results of a global survey. Gerontology 56(1):20–31. https://doi.org/10.1159/000240046 [DOI: 10.1159/000240046]
  19. Baig SA, Hassan M, Ahmed SM et al (2014) A cross-sectional study to investigate pneumococcal vaccination in the elderly in a low income county Patient knowledge, awareness, and attitudes of vaccination and prevalence rates by socioeconomic status. Hum Vacc Immunother 10(4):1024–1027. https://doi.org/10.4161/hv.27697 [DOI: 10.4161/hv.27697]
  20. Ciftci F, Sen E, Demir N, Kayacan O (2017) Which factors effects patients belief and attitudes about influenza vaccination? Tuberk Toraks 65(4):308–316. https://doi.org/10.5578/tt.66324 [DOI: 10.5578/tt.66324]
  21. Akin L, Kaya M, Altinel S, Durand L (2011) Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum Vaccin 7(4):441–450. https://doi.org/10.4161/hv.7.4.14188 [DOI: 10.4161/hv.7.4.14188]
  22. Ahmad Hamidi A, Gelmez Tas B, Gunduz A et al (2018) Immunization rates of pneumococcal, influenza and tetanus vaccines and knowledge and attitudes of adult patients who receive inpatient treatment at hospital: point prevalence study. Hum Vaccin Immunother 14(11):2649–2653. https://doi.org/10.1080/21645515.2018.1489187 [DOI: 10.1080/21645515.2018.1489187]
  23. Korkmaz P, Pasali Kilit T, Onbasi K et al (2019) Influenza vaccination prevalence among the elderly and individuals with chronic disease, and factors affecting vaccination uptake. Cent Eur J Public Health 27(1):44–49. https://doi.org/10.21101/cejph.a5231 [DOI: 10.21101/cejph.a5231]
  24. MacDougall DM, Halperin BA, MacKinnon-Cameron D et al (2015) The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. BMJ Open 5(9):e009062. https://doi.org/10.1136/bmjopen-2015-009062 [DOI: 10.1136/bmjopen-2015-009062]
  25. Islam JY, Gruber JF, Lockhart A et al (2017) Opportunities and challenges of adolescent and adult vaccination administration within pharmacies in the United States. Biomed Inform Insights 9:1178222617692538. https://doi.org/10.1177/1178222617692538 [DOI: 10.1177/1178222617692538]
  26. Couch KA, Geide T (2014) ASHP therapeutic position statement on strategies for identifying and preventing pneumococcal resistance. Am J Health Syst Pharm 71(5):417–424. https://doi.org/10.2146/ajhp130514 [DOI: 10.2146/ajhp130514]
  27. King GS, Judd WR (2017) Impact of a pharmacist-led pneumococcal vaccine compliance program. Am J Health Syst Pharm 74(23):1948–1952. https://doi.org/10.2146/ajhp160916 [DOI: 10.2146/ajhp160916]
  28. Isenor JE, Edwards NT, Alia TA et al (2016) Impact of pharmacists as immunizers on vaccination rates: a systematic review and meta-analysis. Vaccine 34(47):5708–5723. https://doi.org/10.1016/j.vaccine.2016.08.085 [DOI: 10.1016/j.vaccine.2016.08.085]
  29. Eid DD, Meagher RC, Lengel AJ et al (2015) The impact of pharmacist interventions on herpes zoster vaccination rates. Consult Pharm 30(8):459–462. https://doi.org/10.4140/TCP.n.2015.459 [DOI: 10.4140/TCP.n.2015.459]

MeSH Term

Adult
Aged
Female
Herpes Zoster
Herpes Zoster Vaccine
Humans
Male
Middle Aged
Pharmacists
Pneumococcal Infections
Pneumococcal Vaccines
Prospective Studies
Vaccination
Vaccines

Chemicals

Herpes Zoster Vaccine
Pneumococcal Vaccines
Vaccines
Journal Article

Word Cloud

Created with Highcharts 10.0.0vaccinationPNHZinformationpublicvaccinesdiseasesratesvaccinatedstatusparticipantseducationalPneumococcalherpeszosterstudy1 yearprovisiondeterminepharmacistreimbursementrespectively9%7%respectivesessiondiseasepharmacistsBACKGROUND:preventableinfectionsadultpopulationAIMS:aimedidentifypharmacist-ledcommunityobjectivesrevealreasonsopinionsawarenessamongMETHODS:prospectiveconductedfivesocialsolidaritycentresTurkeyParticipantseducatedvaccinationsfollowedtelephone1yearRESULTS:total15572malemeanage6872 ± 904 yearsincludedrespectfound40%12knewFollowingpharmacist's52516%willingvaccine508%gotPerceivedseverityassociatedCONCLUSIONS:obtainfriendsfamilymembersmayresultmisinformationinappropriatebehaviourAlthoughsessionsprovidedincreaseactualwillingnessincreasedconvincegetpneumococcalzoster?HerpesPharmacistVaccinationWillingness

Similar Articles

Cited By (2)